Authors
Loading...
Randomized trial demonstrates enhanced anti-PD-1 efficacy in MSI-H CRC by targeting ELMO1 methylation.
Li et al. (2026) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: